Biomarin Pharmaceutical Inc (BMRN)
65.58
-1.08
(-1.62%)
USD |
NASDAQ |
Nov 14, 16:00
65.58
0.00 (0.00%)
After-Hours: 17:46
Biomarin Pharmaceutical Research and Development Expense (Quarterly): 184.90M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 184.90M |
| June 30, 2024 | 183.79M |
| March 31, 2024 | 204.99M |
| December 31, 2023 | 206.25M |
| September 30, 2023 | 191.31M |
| June 30, 2023 | 177.36M |
| March 31, 2023 | 171.85M |
| December 31, 2022 | 172.75M |
| September 30, 2022 | 157.83M |
| June 30, 2022 | 158.19M |
| March 31, 2022 | 160.84M |
| December 31, 2021 | 161.09M |
| September 30, 2021 | 157.87M |
| June 30, 2021 | 161.11M |
| March 31, 2021 | 148.72M |
| December 31, 2020 | 156.67M |
| September 30, 2020 | 147.05M |
| June 30, 2020 | 182.14M |
| March 31, 2020 | 142.26M |
| December 31, 2019 | 172.81M |
| September 30, 2019 | 172.96M |
| June 30, 2019 | 185.64M |
| March 31, 2019 | 183.59M |
| December 31, 2018 | 175.39M |
| September 30, 2018 | 161.41M |
| Date | Value |
|---|---|
| June 30, 2018 | 175.58M |
| March 31, 2018 | 183.95M |
| December 31, 2017 | 168.61M |
| September 30, 2017 | 154.10M |
| June 30, 2017 | 143.04M |
| March 31, 2017 | 145.00M |
| December 31, 2016 | 175.24M |
| September 30, 2016 | 160.83M |
| June 30, 2016 | 167.04M |
| March 31, 2016 | 158.79M |
| December 31, 2015 | 176.12M |
| September 30, 2015 | 158.71M |
| June 30, 2015 | 157.90M |
| March 31, 2015 | 142.07M |
| December 31, 2014 | 142.07M |
| September 30, 2014 | 125.69M |
| June 30, 2014 | 107.70M |
| March 31, 2014 | 86.17M |
| December 31, 2013 | 97.31M |
| September 30, 2013 | 88.06M |
| June 30, 2013 | 85.66M |
| March 31, 2013 | 83.74M |
| December 31, 2012 | 84.36M |
| September 30, 2012 | 66.21M |
| June 30, 2012 | 77.81M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
142.26M
Minimum
Mar 2020
206.25M
Maximum
Dec 2023
169.99M
Average
166.48M
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co Inc | 5.862B |
| Bristol-Myers Squibb Co | 2.374B |
| Alnylam Pharmaceuticals Inc | 270.93M |
| Repligen Corp | 10.58M |
| Bioventus Inc | 3.808M |